In this study, we analyzed the clinical and genetic characteristics of 48 r/r DLBCL patients receiving CD19/CD22 cocktail CAR T-cell therapy, aiming to characterize the prognostic factors of T cell dysfunction related to the primary resistance mechanism. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.